| |
Visual acuity increase |
Visual acuity steady state |
Visual acuity decrease |
| OCS + CCS group |
17/23 (74 %) |
4/23 (17.4 %) |
2/23 (8.6 %) |
| OCS group |
6/9 (66.7 %) |
1/9 (11.1%) |
2/9 (22.2 %) |
| CCS group |
11/14 (78.5%) |
3/14 (21.4%) |
0/14 (7.1%) |
|
| Table 3.1: Percentage of visual acuity increase, steady state and decrease. |
| |
Visual acuity mean (Log Mar) |
| Baseline |
1 year |
Long term |
ΔVAB –VALT |
Gain in number of lines |
| OCS + CCS group |
1.67 |
1.45 |
1.44 |
0.23 |
2.3 |
| OCS group |
1.74 |
1.60 |
1.43 |
0.31 |
3.1 |
| CCS group |
1.62 |
1.36 |
1.45 |
0.17 |
1.7 |
|
| Table 3.2: Average of visual acuity for all the patients and for OCS and CCS group |
Table 3: Visual acuity evaluation for all the patients (OCS + CCS group), for
patients who received a post-CAOMECS donor graft (OCS group) and for patients
whose stroma was healthy (CCS group)
OCS: opaque corneal stroma, CCS: clear corneal stroma, VA: Visual Acuity, VAB :
Visual acuity baseline, VALT : Visual acuity at long term |
